Mestex AG is a Swiss biotech company developing, among other things, the novel compound MTX-071 (resiniferatoxin) for the intra-articular treatment of pain associated with osteoarthritis of the knee. The previous owners of Mestex AG sold their shares and stock options to the pharmaceutical company Grünenthal, headquartered in Aachen, Germany, a global leader in pain management and related diseases. The promising drug candidate MTX-071 is about to enter phase III clinical trials and could provide an innovative treatment option for millions of patients suffering from pain associated with knee osteoarthritis. With the acquisition, Grünenthal aims to grow in the global market for osteoarthritis drugs and further strengthen its pain treatment-focused pipeline.
VISCHER advises the sellers of Mestex AG on all legal issues related to the transaction. The VISCHER team is led by Christian Wyss (Partner, Corporate/M&A) and Nadia Tarolli (Partner, Tax) with Luzius Zumstein (Associate, Corporate/M&A), Moritz Jäggy (Associate, Corporate/M&A), Pauline Pfirter (Associate, Corporate/M&A), and Adrian Briner (Associate, Tax).
In all matters of German law, VISCHER was supported by Orrick, Herrington & Sutcliffe led by Jörg Ritter and Christine Kaniak.
Read the press releases: